Synlogic, Inc. (SYBX)
NASDAQ: SYBX · Real-Time Price · USD
1.390
-0.010 (-0.71%)
At close: Dec 24, 2024, 12:58 PM
1.410
+0.020 (1.44%)
After-hours: Dec 24, 2024, 2:42 PM EST
Synlogic Revenue
Synlogic had revenue of $2.78M in the twelve months ending September 30, 2024, up 292.23% year-over-year. In the year 2023, Synlogic had annual revenue of $3.37M with 185.68% growth.
Revenue (ttm)
$2.78M
Revenue Growth
+292.23%
P/S Ratio
6.04
Revenue / Employee
$462,833
Employees
6
Market Cap
16.26M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
The Oncology Institute | 378.93M |
Carisma Therapeutics | 20.27M |
Nephros | 13.55M |
bioAffinity Technologies | 9.37M |
BioXcel Therapeutics | 2.28M |
Adagio Medical Holdings | 543.00K |
SYBX News
- 6 weeks ago - Synlogic Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 4 months ago - Synlogic Reports Second Quarter 2024 Financial Results - GlobeNewsWire
- 8 months ago - Synlogic Reports First Quarter 2024 Financial Results - GlobeNewsWire
- 10 months ago - Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire
- 11 months ago - Synlogic Adopts Limited Duration Stockholders Rights Plan - GlobeNewsWire
- 11 months ago - Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update - GlobeNewsWire
- 11 months ago - Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria - GlobeNewsWire
- 1 year ago - Synlogic Provides Corporate Update and Outlook for 2024 - GlobeNewsWire